Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01817374 · ClinicalTrials.gov registry record · NA
Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
A NA study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01817374 is a NA study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants.
The verdict
NCT01817374, a NA study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale ultrasound and post-treatment mammography findings utilizing final surgical pathology and clinical outcome. 2. Assess incremental benefit of quantitative VCEUS to planar CEUS tumor perfusion measurements and enhancement patterns in predicting tumor response to adjuvant treatment in clinical studies. The contrast agent Definity® is FDA approved for use as a contrast agent during ultrasound (echocardiography) of the heart. Definity® will be used "off-label" (during ultrasound of the breast) in this study. The administration of Definity® during this study will follow total dose guidelines approved by the FDA.
Interventions
- DIAGNOSTIC_TEST 2D US grayscale plus quantitative VCEUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01817374
The ClinicalTrials.gov registry entry for NCT01817374 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2D US grayscale plus quantitative VCEUS is the first listed.
NCT01817374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01817374 about?
NCT01817374 is a clinical study titled "Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy". 1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale ultrasound and post-treatment mammography findings utilizing final surgical pathology and clinical outcome. 2. Assess incremen...
What is the current status of trial NCT01817374?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2015-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01817374?
The interventions under investigation include: 2D US grayscale plus quantitative VCEUS (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01817374?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.